<?xml version="1.0" encoding="UTF-8"?>
<p>At this time, the neurological complications of COVID-19 are not fully understood, but reports of prominent neurological symptoms and complications are beginning to emerge.
 <xref rid="bib1" ref-type="bibr">
  <sup>1</sup>
 </xref> The current incidence of neurological findings with COVID-19 is relatively low, but as data from prior epidemics show, particularly prior coronavirus-related epidemics, the rate is likely to further increase. Neurological manifestations, including headache, dizziness, altered level of consciousness, focal neurological deficits, cranial nerve involvement,
 <xref rid="bib2" ref-type="bibr">
  <sup>2</sup>
 </xref> seizures, and to a lesser extent meningoencephalitis,
 <xref rid="bib3" ref-type="bibr">
  <sup>3</sup>
 </xref> more severe necrotizing encephalopathy,
 <xref rid="bib4" ref-type="bibr">
  <sup>4</sup>
 </xref> cerebral edema, and stroke,
 <xref rid="bib5" ref-type="bibr">
  <sup>5</sup>
 </xref> have been reported with the recent viral epidemics. Importantly, with prior epidemics (Table 
 <xref rid="tbl3" ref-type="table">3</xref>), there are also several reports of patients developing neurological sequelae months to weeks later, including cerebellitis,
 <xref rid="bib6" ref-type="bibr">
  <sup>6</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib7" ref-type="bibr">
  <sup>7</sup>
 </xref> neuropathy,
 <xref rid="bib8" ref-type="bibr">
  <sup>8</sup>
 </xref> Guillain-Barr√© syndrome,
 <xref rid="bib9" ref-type="bibr">
  <sup>9</sup>
 </xref> postinfluenza myositis,
 <xref rid="bib10" ref-type="bibr">
  <sup>10</sup>
 </xref> and postviral Parkinsonism.
 <xref rid="bib11" ref-type="bibr">
  <sup>11</sup>
 </xref>
</p>
